Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug;12(11):819-831.
doi: 10.2217/imt-2020-0054. Epub 2020 Jun 29.

The immunotherapy revolution in genitourinary malignancies

Shruti U Gandhy  1 , Ravi A Madan  1 , Jeanny B Aragon-Ching  2
Affiliations
Review

The immunotherapy revolution in genitourinary malignancies

Shruti U Gandhy et al. Immunotherapy. 2020 Aug.

Abstract

Immune checkpoint inhibitor (ICI) therapy and therapeutic cancer vaccines have continued to demonstrate survival benefit and durable clinical response in patients with renal cell cancer, prostate cancer and bladder cancer, with limited responses in testicular cancer. The role of immunotherapy in combination with chemotherapy or other targeted therapies in the neo-adjuvant, adjuvant and metastatic setting is actively being explored. We describe the current immunotherapy-related treatment modalities approved for genitourinary cancers, focusing on immune checkpoint inhibitors, vaccines and other modalities, and highlight ongoing studies involving immunotherapy in these cancer types.

Keywords: CTLA-4; PD-1; PD-L1; bladder cancer; genitourinary malignancies; immune checkpoint inhibitors; prostate cancer; renal cell carcinoma; testicular cancer; vaccines.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

J Aragon-Ching serves on the Speakers' Bureau for BMS, Astellas/Seattle Genetics and serves on the Advisory Board for EMD Serono. SU Gandhy and RA Madan have no conflicts to declare. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References

    1. Hodi FS, O'Day SJ, McDermott DF. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723 (2010). - PMC - PubMed
    1. Brahmer JR, Tykodi SS, Chow LQM. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455–2465 (2012). - PMC - PubMed
    1. Garon EB, Rizvi NA, Hui R. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372(21), 2018–2028 (2015). - PubMed
    1. Mahoney KM, Atkins MB. Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park) 28(Suppl. 3), 39–48 (2014). - PubMed
    1. Le DT, Uram JN, Wang H. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372(26), 2509–2520 (2015). - PMC - PubMed

MeSH terms